- Investor Presentation
LBT Announces Completion of $7 Million Placement
New Institutional Investors and directors back LBT Innovations’ commercialisation strategy.
MergerMarket publishes: MicroStreak options to shift focus to APAS
LBT Innovations [ASX:LBT], an Australian medical technology company, is considering options for its MicroStreak technology as it shifts its focus to its Automated Plate Assessment Systems (APAS) platform, said new CEO and MD Brent Barnes
- Results of Annual General Meeting
Company OverviewOver the past decade, LBT Innovations has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefi...
MicroStreakIn its first five years of global sales, LBT’s MicroStreak technology captured the largest share of the international market for automated culture-plate streaking and inoculation. Originally sold by bi...
APASThe Automated Plate Assessment System, or APAS, is a platform technology for the automation of culture-plate screening and interpretation. While LBT’s first product, PREVI Isola, automates the inoculati...